Hopkinton-based drug research company Caliper Life Sciences Inc. reported a first-quarter net loss of $9.6 million on revenue of $28.4 million.
For the same quarter the previous year, the company reported a net loss of $4.4 million.
The company said the loss is the result of its acquisition of Xenogen Corp., a biotechnology company also based in Hopkinton.
But without Xenogen, the picture would have been worse. The company said Xenogen revenue offset a decline in “automation revenue,” unfavorable quarter-to-quarter sales, and “timing delays in technology spending by certain large customers.”
Revenue for the quarter was 28 percent more than the same period of the previous year. The company predicted 23 to 44 percent growth in the second quarter, and 27 to 33 percent revenue growth for the remainder of the year.
